Method and compositions for the treatment of cerebral palsy
AssigneeAllergan, Inc.
InventorHerbert Kerr Graham
Life of this patent
Estimating the term…
Abstract
The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin B) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.
Claims8
A method for treating juvenile cerebral palsy, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin type B to a juvenile cerebral palsy patient, thereby treating juvenile cerebral palsy.
A method of treating juvenile cerebral palsy, the method comprising the step of administering at least 1000 units of a botulinum toxin type B to a juvenile cerebral palsy patient, thereby treating juvenile cerebral palsy.
Dependencies are inferred from the claim text.